CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.
January 13th 2022
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
January 13th 2022
Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial.
January 10th 2022
The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.
January 5th 2022
An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.
January 4th 2022
From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.
December 24th 2021
Patients with cancer who received two full vaccine doses but developed breakthrough COVID-19 infections afterwards had a 13% mortality rate as well as a high hospitalization risk, and therefore should maintain protective strategies, according to experts.
December 23rd 2021
New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.
December 21st 2021
A certified oncology nurse and board-certified adult nurse practitioner explained how the recent FDA approval of Darzalex Faspro, Kyprolis and dexamethasone may allow patients with relapsed/refractory multiple myeloma to switch treatments after discovering their current treatment is no longer working.
December 15th 2021
Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.
December 15th 2021
Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.
December 13th 2021
Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.
December 12th 2021
Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.
December 10th 2021
In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.
December 9th 2021
On this episode of the “Cancer Horizons” podcast, a woman with multiple myeloma shares how she made the best of her cancer treatment process by channeling her emotions through fashion expression.
December 1st 2021
The FDA approved the three-drug regimen of Darzalex Faspro, Kyprolis and dexamethasone for patients with pretreated relapsed/refractory multiple myeloma.
November 23rd 2021
Darzalex plus Revlimid and dexamethasone may be the preferred option to treat older patients with multiple myeloma who are ineligible for stem-cell transplant.
November 19th 2021
An expert explains how two common myeloma treatments – CAR-T cell therapy and bi-specific antibodies – work, and which patients may want to steer clear from these treatment modalities.
October 22nd 2021
Myeloma survivors, their loved ones and clinicians trekked up the Alaska-Kenai Peninsula to raise money and funds for the disease, offering one nurse the inspiration she needed after more than a year of the COVID-19 pandemic.
October 19th 2021
Engineered cell technology is an example of ingenuity that brings together cutting-edge laboratory science and clinical trials to address aggressive cancers.
October 18th 2021
Colin Powell has died of complications from COVID-19 after receiving treatment for a blood cancer.
October 18th 2021
After receiving a diagnosis of multiple myeloma, a patient relied on the Multiple Myeloma Research Foundation for information and is becoming part of the conversation.
October 11th 2021
Natural killer cell therapy is making strides in blood cancer research, but there’s still much more to learn.
October 7th 2021
Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.
October 5th 2021
Patients with myeloma should not be afraid to seek out second opinions or speak up about side effects that they are experiencing.
October 2nd 2021
View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.
September 23rd 2021
The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.
September 2nd 2021
The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.
August 19th 2021
Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.
July 31st 2021
Fifteen percent of patients with myeloma did not have detectable antibodies two weeks after receiving the COVID-19 vaccine.